SynthesisJournal of hematology & oncology2014
Tissue factor in tumor microenvironment: a systematic review.
Synthesis in Journal of hematology & oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 85 citations in OpenAlex.
- Trial
- Hemostasis at the edge between physiology and cancer.Internal and emergency medicine · 2026Review
- Tissue factor targeted near-infrared photoimmunotherapy: a versatile therapeutic approach for malignancies.Cancer immunology, immunotherapy : CII · 2025Article
- Combined CA125, NSE, and multiple inflammatory indices for diagnosis of oral squamous cell carcinoma.Frontiers in oncology · 2025Article
- Tissue factor expression in salivary gland carcinoma: a potential novel therapeutic target for advanced disease.Therapeutic advances in medical oncology · 2025Article
- O-GlcNAcylation: Crosstalk between Hemostasis, Inflammation, and Cancer.International journal of molecular sciences · 2024Review
- An idiosyncratic zonated stroma encapsulates desmoplastic liver metastases and originates from injured liver.Nature communications · 2023Article
- Amygdalin-folic acid-nanoparticles inhibit the proliferation of breast cancer and enhance the effect of radiotherapy through the modulation of tumor-promoting factors/ immunosuppressive modulators in vitro.BMC complementary medicine and therapies · 2023Article
- Hypoxia Changes Energy Metabolism and Growth Rate in Non-Small Cell Lung Cancer Cells.Cancers · 2023Article
- Microparticle Phosphatidylserine Mediates Coagulation: Involvement in Tumor Progression and Metastasis.Cancers · 2023Review
- Advancement and Applications of Platelet-inspired Nanoparticles: A Paradigm for Cancer Targeting.Current pharmaceutical biotechnology · 2023Review
- Expression patterns of uPAR, TF and EGFR and their potential as targets for molecular imaging in oropharyngeal squamous cell carcinoma.Oncology reports · 2022Article
- Tissue factor: a neglected role in cancer biology.Journal of thrombosis and thrombolysis · 2022Review
- Beyond Hemostasis: Platelet Innate Immune Interactions and Thromboinflammation.International journal of molecular sciences · 2022Review
- Effectiveness and Safety of the Traditional Chinese Medicine Treatment (Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Small extracellular vesicles in cancer.Bioactive materials · 2021Review
- Bacitracin and Rutin Regulate Tissue Factor Production in Inflammatory Monocytes and Acute Myeloid Leukemia Blasts.Cancers · 2021Article
- Article
- Golden berry 4β-hydroxywithanolide E prevents tumor necrosis factor α-induced procoagulant activity with enhanced cytotoxicity against human lung cancer cells.Scientific reports · 2021Article
- Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aberrant hemostasis is a common manifestation of cancer, and venous thromboembolism (VTE) is the second leading cause of cancer patients' mortality. Tissue factor (TF), comprising of a 47-kDa transmembrane protein that presents in subendothelial tissues and leukocytes and a soluble isoform, have distinct roles in the initiation of extrinsic coagulation cascade and thrombosis. Laboratory and clinical evidence showed the deviant expression of TF in several cancer systems and its tumor-promoting effects. TF contributes to myeloid cell recruitment in tumor stroma, thereby remodeling of tumor microenvironment. Additionally, the number of TF-positive-microparticles (TF+MP) from tumor origins correlates with the VTE rates in cancer patients. In this review, we summarize our current understanding of the TF regulation and roles in tumor progression and clinical complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.